Trikafta 80-40-60MG/59.5MG PKT 14S
Ended Awarded Last action
- Contract number
- SPE2DR26FDDT1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,357
Award facts
- Contract value 100% obligated
- $19,357.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has awarded a delivery order valued at $19,357.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Trikafta 80-40-60mg/59.5mg packets (14-count). This firm fixed-price delivery order, issued on January 16, 2026, with an ultimate completion date of January 20, 2026, carries no set-aside designation, reflecting the vendor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established on November 13, 2025, with a $499.999 billion ceiling and completion date of December 31, 2036.
As a critical pharmaceutical supplier within the Department of Defense's medical supply chain, DMS Pharmaceutical Group leverages its small business status and established performance record to fulfill recurring pharmaceutical needs for military healthcare facilities worldwide. The PPV-G GEN V program, part of a broader $30.3 billion acquisition strategy, enables the Defense Logistics Agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, vaccines, and medical consumables. DMS Pharmaceutical Group's demonstrated capability across diverse therapeutic categories, including specialty pharmaceuticals and emergency medications, positions the company as a key regional prime vendor contractor supporting Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FDDT1?
SPE2DR26FDDT1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 16, 2026.
How much is contract SPE2DR26FDDT1 worth?
The government has obligated $19,357 on SPE2DR26FDDT1.
Is contract SPE2DR26FDDT1 an order under another contract?
Yes. SPE2DR26FDDT1 is a delivery order under SPE2DR25D9102, an indefinite delivery contract.
Was contract SPE2DR26FDDT1 competed?
The extent of competition for SPE2DR26FDDT1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award